Conduit Pharmaceuticals Files 8-K/A Amendment
Ticker: CDTTW · Form: 8-K/A · Filed: Jul 11, 2024 · CIK: 1896212
| Field | Detail |
|---|---|
| Company | Conduit Pharmaceuticals Inc. (CDTTW) |
| Form Type | 8-K/A |
| Filed Date | Jul 11, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, governance, shareholder-nominations
TL;DR
Conduit Pharma filed an 8-K/A amendment on shareholder nominations. Keep an eye on governance changes.
AI Summary
Conduit Pharmaceuticals Inc. filed an amendment (8-K/A) on July 11, 2024, regarding shareholder nominations under Exchange Act Rule 14a-11. The filing pertains to the company's common stock and redeemable warrants, with the earliest reported event date being July 1, 2024. Conduit Pharmaceuticals Inc. is incorporated in Delaware and its principal executive offices are located in San Diego, CA.
Why It Matters
This amendment clarifies details related to shareholder nominations, which could impact corporate governance and future strategic decisions for Conduit Pharmaceuticals Inc.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous report and does not introduce new material events or financial distress.
Key Numbers
- 0.0001 — Par Value Per Share (Common Stock)
- 11.50 — Exercise Price (Redeemable Warrants)
Key Players & Entities
- Conduit Pharmaceuticals Inc. (company) — Registrant
- July 1, 2024 (date) — Earliest event reported date
- July 11, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- San Diego, CA (location) — Business address
- Murphy Canyon Acquisition Corp. (company) — Former company name
FAQ
What specific shareholder nominations are being addressed in this amendment?
The filing is an amendment to a previous report concerning shareholder nominations pursuant to Exchange Act Rule 14a-11, but the specific details of the nominations are not elaborated in the provided text.
What is the significance of the earliest reported event date being July 1, 2024?
The earliest reported event date of July 1, 2024, indicates the date on which the events or actions related to the filing (shareholder nominations) occurred or became effective.
What is the business of Conduit Pharmaceuticals Inc.?
Conduit Pharmaceuticals Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
When did Conduit Pharmaceuticals Inc. change its name from Murphy Canyon Acquisition Corp.?
The date of the name change from Murphy Canyon Acquisition Corp. to Conduit Pharmaceuticals Inc. was November 30, 2021.
What is the exercise price for the redeemable warrants?
The redeemable warrants have an exercise price of $11.50 per share.
Filing Stats: 625 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2024-07-11 16:15:41
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CDT The Nasdaq
- $11.50 — of Common Stock at an exercise price of $11.50 CDTTW The Nasdaq Stock Market LLC
Filing Documents
- form8-ka.htm (8-K/A) — 41KB
- 0001493152-24-026957.txt ( ) — 261KB
- cdt-20240701.xsd (EX-101.SCH) — 4KB
- cdt-20240701_def.xml (EX-101.DEF) — 26KB
- cdt-20240701_lab.xml (EX-101.LAB) — 36KB
- cdt-20240701_pre.xml (EX-101.PRE) — 25KB
- form8-ka_htm.xml (XML) — 7KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 11, 2024 CONDUIT PHARMACEUTICALS INC. By: /s/ Dr. David Tapolczay Name: Dr. David Tapolczay Title: Chief Executive Officer